Ravulizumab

瑞利珠单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRavulizumab
Drug Alias NameRavulizumab-CwvzUltomiris伟立瑞ALXN-1810ALXN-1210
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Immunoglobulin A Vasculitis Associated Nephritis +[22] 
Global Approved IndicationsHemoglobinuria, ParoxysmalKidney Diseases
Approved Indications in ChinaKidney Diseases
Original Approved Country/TerritoryUnited States
Original Approved Date2018/12/21
Country/TerritoryCzechiaBelgiumCanada +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlexion Pharmaceuticals IncXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalAlexion Athlone Manufacturing FacilityAlexion Europe Sas +[6] 
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Immunoglobulin A Vasculitis Associated Nephritis +[16] 
Inactive IndicationsLupus NephritisAmyotrophic Lateral SclerosisRespiratory Distress Syndrome, Adult +[6] 

Other Information

ATC CodeL04AJ02
Related LinksWikipediaDrugBankKEGG